LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

§ 01 Executive Snapshot

• What: Lunai Bioworks updates shareholders on strategic advancements in biotechnology and national security.
• Who: Lunai Bioworks, U.S. government, BioSymetrics, Pathfinder Consortium, Harvard University, and other institutional partners.
• Why it matters: The company's initiatives position it at the forefront of biodefense and precision neurology, areas of increasing national security relevance.

§ 02 Key Developments

• In April 2026, Lunai secured a revenue-generating, multi-year defense collaboration with BioSymetrics for AI-enabled chemical threat assessment.
• Established the Pathfinder Consortium, partnering with leading institutions such as Harvard and the University of Utah to enhance biodefense capabilities.
• Received a Phase I/II STTR grant of $1.85 million awarded to BioSymetrics for alcohol use disorder research, validating their biology-first discovery approach.

§ 03 Strategic Context

• The convergence of AI and biotechnology is becoming critical in national security, particularly in addressing biological threats and pandemics.
• The 2027 Defense Authorization Bill emphasizes the need for advanced biological screening, aligning with Lunai's strategic focus on AI-driven threat identification.

§ 04 Strategic Implications

• Immediate implications include strengthened partnerships and revenue streams enhancing Lunai's market position in biodefense.
• Long-term implications involve the potential for significant growth in precision neurology and biodefense markets as government investment increases.

§ 05 Risks & Constraints

• Potential risks include regulatory scrutiny and legal challenges related to the ongoing litigation against alleged market manipulation.
• The company may face competition from other biotech firms and the complexities of navigating government contracts and partnerships.

§ 06 Watchlist / Forward Signals

• Upcoming milestones include progress in litigation to restore shareholder value and advancements in biodefense and neurology programs.
• The success of the Augusta platform and the expansion of partnerships in biodefense will signal Lunai's growth trajectory moving forward.